Clarivate have released their ‘Drugs to Watch 2023’ listing – the report includes information on the key trends, such as:

  • The growing market in mainland China
  • The impending loss of exclusivity of HUMIRA
  • COVID-19 vaccines and therapies
  • Personalized medicines’ move from promise to reality
  • How sustainable goals encourage innovative solutions

Download the report from: